



Roche Medical Affairs invites you to
The 15th Annual

HOTT™ SYMPOSIUM

Harnessing Oncology Targeted Therapies

INVITATION

Friday 24 - Saturday 25 March 2017

Hyatt Regency, Sydney

(formerly known as Four Points by Sheraton)

To register your attendance, please visit: <http://www.hott2017nz.dcim.com.au>

RSVP by Tuesday 14 February 2017

For further information contact: Stuart Ryan – Medical and Clinical Manager
by phone 09 523 9403 or 021 769 089 or email stuart.ryan@roche.com

Friday 24 March 2017

6.30pm–9.30pm **Welcome Function**

Saturday 25 March 2017

CONCURRENT SESSIONS

8.00am–9.30am

Breast Cancer

Triple negative breast cancer: the final frontier

Chair: A/Prof Jane Beith
Prof Geoffrey Shapiro

Lung Cancer

Navigating immunotherapy in lung cancer today and tomorrow

Chairs: Prof Ken O'Byrne, A/Prof Tom John

Recent developments in Cancer Immunotherapy (CIT)

A/Prof Nick Pavlakis

Biomarkers?

Speaker (TBC)

Who should we treat and for how long?

A/Prof Paul Mitchell

Future approaches and directions in CIT

Dr Dominik Ruettinger

9.30am–10.00am

MORNING TEA

CONCURRENT SESSIONS

10.00am–12.00pm

Gynaecological Cancer

Advances in targeted therapies for ovarian and cervical cancers

Chair: Dr Michelle Harrison

Where to start with treatment in ovarian cancer: neoadjuvant chemotherapy or primary debulking surgery?

A/Prof Trevor Tegada-Berges

Incorporating maintenance therapy in advanced ovarian cancer

Prof Bradley Monk

Difficult cases for the MDT
Speakers: Dr Michelle Harrison, Med-Onc, A/Prof Trevor Tegada-Berges, Gynae-Onc, Dr Karen Lim, Rad-Onc

Panel: Prof Bradley Monk, Dr Michelle Harrison, Dr Jeffrey Goh, Dr Sumitra Ananda, Dr Pearly Khaw

Gastrointestinal Cancer

Molecular markers in colorectal cancer: is it as simple as side?

Chair: Prof Tim Price

Perspectives on choosing a therapy in metastatic colorectal cancer

Prof Cornelis Punt

Biomarkers in CRC

Dr Jeanne Tie

MDT Panel discussion

Speakers: Prof Tim Price, A/Prof Peter Gibbs

Panel: Prof Cornelis Punt, Prof Tim Price, A/Prof Peter Gibbs, Rad-onc (TBC), Surgeon (TBC)

Melanoma

BRAF+ mutated metastatic melanoma: patient-centric management

Chair: Prof Grant McArthur

The biology of the immunological response

Prof Roger Lo

The clinical trial landscape

Prof Georgina Long

How do we make our choices?

Prof Grant McArthur, Prof Roger Lo, Dr Vic Atkinson, Prof Georgina Long, Prof Richard Scolyer,

Dr Alexander Menzies

The 15th Annual

HOTT™ SYMPOSIUM

Harnessing Oncology Targeted Therapies

12.00pm–1.00pm LUNCH

CONCURRENT SESSIONS

1.00pm–2.30pm

Breast Cancer

Improving the patient journey in metastatic breast cancer

Chair: A/Prof Nicole McCarthy

The rising role of patient reported outcomes
Dr Manfred Welslau

Challenging case studies in HER2+ mBC
Speakers (TBC)

Rare Cancers

Optimising treatment for patients with advanced/metastatic basal cell carcinoma

Chair: Prof Grant McArthur

Key clinical data overview
Prof Aleksandar Sekulic

Virtual aBCC/mBCC MDT
Panel: Prof Aleksandar Sekulic, Prof Jonathan Clark, A/Prof Alex Guminski, Prof Bryan Burmiester

2.30pm–3.00pm AFTERNOON TEA

PLENARY SESSION

3.00pm–4.00pm

Future management of cancer, is the organ irrelevant?
A debate moderated by Norman Swan

4.00pm

Delegates depart

The 15th Annual

HOTT™ SYMPOSIUM

Harnessing Oncology Targeted Therapies

INVITED INTERNATIONAL SPEAKERS

Prof Roger Lo *USA* (MEDICINE/DERMATOLOGY AND MOLECULAR AND MEDICAL PHARMACOLOGY)

David Geffen School of Medicine at UCLA

Prof Bradley Monk *USA* (GYNAECOLOGICAL CANCER)

University of Arizona Cancer Center

Prof Cornelis Punt *the Netherlands* (GASTROINTESTINAL CANCER)

University of Amsterdam

Dr Dominik Ruettinger *Germany* (LUNG CANCER)

Group Head Translational Medicine Oncology, Roche Innovation Center and
Pharma Research and Early Development (pRED), Roche Diagnostics GmbH

Prof Aleksandar Sekulic *USA* (DERMATOLOGY)

Mayo Clinic and the Translational Genomics Research Institute

Prof Geoffrey Shapiro *USA* (DEVELOPMENTAL THERAPEUTICS)

Dana-Farber Cancer Institute

Dr Manfred Welslau *Germany* (BREAST CANCER)

Onkologie Aschaffenburg

Roche is pleased to support the cost of return economy flights, airport transfers, accommodation and meals for the duration of the meeting. In line with the Medicines New Zealand Code of Practice, flights, transfers and hospitality can only be extended to healthcare professionals invited as delegates. Your accommodation package includes your breakfast only; any additional charges will be payable at check-out.

Personal information that Roche collects from you will only be used for the purposes for which it is collected. Roche will not use or disclose any personal information for any other purpose without your consent (except where Roche is required or permitted by law to disclose it). If you wish to access or request correction of any personal information Roche or its affiliates holds about you, please contact Roche's Privacy Officer at nz.info@roche.com.

Roche Products (New Zealand) Limited, PO Box 109113, Newmarket, Auckland 1149. Freephone 0800 656 464, Fax 09 523 9465.

NPM-NZ-0014